Stories from people navigating diabetes — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Cardiology
A 2026 meta-analysis estimated 32% lower odds of major cardiovascular events with semaglutide. The result supports cardiovascular benefit discussions but requires context on heterogeneity, absolute risk and indication.
Dr. Abu Bakar · September 13, 2026 · 6 min
Cardiology
The 2026 multisociety guideline defines a unified pathway for evaluating cardiovascular, kidney and metabolic risk, particularly when disease or risk factors overlap.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.